We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow. In this article, we are going to take a ...

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Shares of Merck & Co. Inc. MRK slid 1.72% to $96.24 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and ...

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...

Merck & Co Inc (MRK) stock saw a decline, ending the day at $96.24 which represents a decrease of $-1.68 or -1.72% from the prior close of $97.92. The stock opened at $98.08 and touched a low of ...